{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:43:51Z","timestamp":1793371431200,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"DOI":"10.1007\/s12308-026-00739-w","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:18:40Z","timestamp":1791515920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EBV-positive Hodgkin lymphoma with an immunosuppressive microenvironment during guselkumab (interleukin-23 inhibitor) therapy for chronic plaque psoriasis"],"prefix":"10.1007","volume":"19","author":[{"given":"Bhaumik","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Franco-Barraza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy Q.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariia","family":"Dmitrieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Cukierman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nejati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"3","key":"739_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB et al (2022) Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol 74(3):475\u2013485","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"739_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43435-w","volume":"13","author":"F Rivest","year":"2023","unstructured":"Rivest F et al (2023) Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics. Sci Rep 13(1):16994","journal-title":"Sci Rep"},{"issue":"17","key":"739_CR3","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1182\/bloodadvances.2017007260","volume":"1","author":"AS Duffield","year":"2017","unstructured":"Duffield AS et al (2017) Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. Blood Adv 1(17):1324\u20131334","journal-title":"Blood Adv"},{"issue":"3","key":"739_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/ajcp\/aqad053","volume":"160","author":"C Batuello","year":"2023","unstructured":"Batuello C, Mason EF (2023) Diagnostic utility of CD200 immunohistochemistry in distinguishing EBV-positive large B-cell lymphoma from classic Hodgkin lymphoma. Am J Clin Pathol 160(3):284\u2013291","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"739_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1128\/JVI.01437-14","volume":"89","author":"PM Hau","year":"2015","unstructured":"Hau PM et al (2015) Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells. J Virol 89(1):652\u2013668","journal-title":"J Virol"},{"issue":"10","key":"739_CR6","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","volume":"126","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM et al (2006) The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126(10):2194\u20132201","journal-title":"J Invest Dermatol"},{"issue":"2","key":"739_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","volume":"11","author":"A Menter","year":"2021","unstructured":"Menter A et al (2021) Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb) 11(2):385\u2013400","journal-title":"Dermatol Ther (Heidelb)"},{"key":"739_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jdin.2024.06.006","volume":"17","author":"M Vangilbergen","year":"2024","unstructured":"Vangilbergen M et al (2024) The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: a systematic review. JAAD Int 17:71\u201379","journal-title":"JAAD Int"},{"issue":"1","key":"739_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","volume":"47","author":"B Strober","year":"2024","unstructured":"Strober B et al (2024) Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf 47(1):39\u201357","journal-title":"Drug Saf"},{"issue":"1","key":"739_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/bjd\/ljad115","volume":"189","author":"MG Lebwohl","year":"2023","unstructured":"Lebwohl MG et al (2023) Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure. Br J Dermatol 189(1):42\u201352","journal-title":"Br J Dermatol"},{"issue":"2","key":"739_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","volume":"89","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A et al (2023) Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 89(2):274\u2013282","journal-title":"J Am Acad Dermatol"},{"key":"739_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294416","volume":"14","author":"S Wu","year":"2023","unstructured":"Wu S et al (2023) Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol 14:1294416","journal-title":"Front Immunol"},{"issue":"2","key":"739_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jdv.19520","volume":"38","author":"K Kridin","year":"2024","unstructured":"Kridin K et al (2024) Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study. J Eur Acad Dermatol Venereol 38(2):315\u2013324","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"739_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/1346-8138.17255","volume":"51","author":"Y Tada","year":"2024","unstructured":"Tada Y et al (2024) Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study. J Dermatol 51(6):779\u2013790","journal-title":"J Dermatol"},{"key":"739_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050991","author":"AS Torne","year":"2024","unstructured":"Torne AS, Robertson ES (2024) Epigenetic mechanisms in latent Epstein-Barr virus infection and associated cancers. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16050991","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-026-00739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-026-00739-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-026-00739-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:18:43Z","timestamp":1791515923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-026-00739-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s12308-026-00739-w","relation":{},"ISSN":["1865-5785"],"issn-type":[{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All biospecimens and clinical data used in this tumor microenvironment study were originally collected as part of routine patient care; no additional specimen collection was performed for research purposes. The study received ethical approval from the Institutional Review Board of Fox Chase Cancer Center. The submitted material does not contain any information or identifiers that could be used, alone or in combination, to directly or indirectly identify any individual subject of the case report.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for use of clinical details and images in this manuscript.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"64"}}